Fulgent Genetics (FLGT) 10-Q 12 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	FLGT
Entity Registrant Name	Fulgent Genetics, Inc.
Entity Central Index Key	0001674930
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		18,421,792
Entity File Number	001-37894
Entity Tax Identification Number	812621304
Entity Address, Address Line One	4978 Santa Anita Avenue, Suite 205
Entity Address, City or Town	Temple City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91780
City Area Code	626
Local Phone Number	350-0537

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 9,165	$ 6,736
Marketable securities	17,820	24,298
Trade accounts receivable, net of allowance for doubtful accounts of $585 and $590, as of June 30, 2019 and December 31, 2018, respectively	5,543	5,948
Other current assets	2,267	2,561
Total current assets	34,795	39,543
Marketable securities, long-term	11,697	6,386
Equity method investments	1,084	1,512
Fixed assets, net	5,937	6,446
Operating lease right-of-use asset	2,756
Other long-term assets	167	17
Total assets	56,436	53,904
Current liabilities
Accounts payable	1,175	1,313
Accrued liabilities	1,333	1,425
Operating lease liabilities, short-term	401
Total current liabilities	2,909	2,738
Operating lease liabilities, long-term	2,385
Other long-term liabilities		14
Total liabilities	5,294	2,752
Commitments and contingencies (Note 8)
Stockholders’ equity
Common stock, $0.0001 par value per share, 50,000 shares authorized, 18,393 and 18,172 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	2	2
Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at June 30, 2019 and December 31, 2018
Additional paid-in capital	115,532	114,203
Accumulated other comprehensive income (loss)	203	(35)
Accumulated deficit	(64,595)	(63,018)
Total stockholders’ equity	51,142	51,152
Total liabilities and stockholders’ equity	$ 56,436	$ 53,904

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 585	$ 590
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	18,393,000	18,172,000
Common stock, shares outstanding	18,393,000	18,172,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Revenue	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Cost of revenue	3,620	2,544	6,588	5,316
Gross profit	4,804	2,856	7,206	4,737
Operating expenses:
Research and development	1,574	1,212	2,998	2,670
Selling and marketing	1,304	1,279	2,576	2,409
General and administrative	1,631	1,366	3,160	2,853
Total operating expenses	4,509	3,857	8,734	7,932
Operating income (loss)	295	(1,001)	(1,528)	(3,195)
Interest and other income, net	192	98	399	193
Income (loss) before income taxes and equity loss in investee	487	(903)	(1,129)	(3,002)
Provision for (benefit from) income taxes	7	(100)	20	(534)
Income (loss) before equity loss in investee	480	(803)	(1,149)	(2,468)
Equity loss in investee	(149)	(246)	(428)	(491)
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Net income (loss) per common share:
Basic	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Diluted	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Weighted-average common shares:
Basic	18,343	17,919	18,286	17,891
Diluted	19,021	17,919	18,286	17,891

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Other comprehensive income (loss):
Foreign currency translation gain (loss)	(14)	(43)	1	(21)
Net unrealized gain (loss) on marketable securities, net of tax	122	48	237	(17)
Comprehensive income (loss)	$ 439	$ (1,044)	$ (1,339)	$ (2,997)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Stockholders' Equity	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning Balance at Dec. 31, 2017	$ 54,178	$ 2	$ 111,884	$ (44)	$ (57,664)
Beginning Balance, Shares at Dec. 31, 2017		17,847,000
Equity-based compensation	1,118		1,118
Exercise of common stock options	9		9
Exercise of common stock options, Shares		23,000
Restricted stock awards, Shares		93,000
Cumulative effect of accounting change	327				327
Cumulative tax effect of accounting change	(74)				(74)
Other comprehensive gain (loss), net	(38)			(38)
Net income (loss)	(2,959)				(2,959)
Ending Balance at Jun. 30, 2018	52,561	$ 2	113,011	(82)	(60,370)
Ending Balance, Shares at Jun. 30, 2018		17,963,000
Beginning Balance at Mar. 31, 2018	53,025	$ 2	112,431	(87)	(59,321)
Beginning Balance, Shares at Mar. 31, 2018		17,876,000
Equity-based compensation	573		573
Exercise of common stock options	7		7
Exercise of common stock options, Shares		18,000
Restricted stock awards, Shares		69,000
Other comprehensive gain (loss), net	5			5
Net income (loss)	(1,049)				(1,049)
Ending Balance at Jun. 30, 2018	52,561	$ 2	113,011	(82)	(60,370)
Ending Balance, Shares at Jun. 30, 2018		17,963,000
Beginning Balance at Dec. 31, 2018	$ 51,152	$ 2	114,203	(35)	(63,018)
Beginning Balance, Shares at Dec. 31, 2018	18,172,000	18,172,000
Equity-based compensation	$ 1,320		1,320
Exercise of common stock options	9		9
Exercise of common stock options, Shares		24,000
Restricted stock awards, Shares		197,000
Other comprehensive gain (loss), net	238			238
Net income (loss)	(1,577)				(1,577)
Ending Balance at Jun. 30, 2019	$ 51,142	$ 2	115,532	203	(64,595)
Ending Balance, Shares at Jun. 30, 2019	18,393,000	18,393,000
Beginning Balance at Mar. 31, 2019	$ 49,961	$ 2	114,790	95	(64,926)
Beginning Balance, Shares at Mar. 31, 2019		18,286,000
Equity-based compensation	737		737
Exercise of common stock options	5		5
Exercise of common stock options, Shares		15,000
Restricted stock awards, Shares		92,000
Other comprehensive gain (loss), net	108			108
Net income (loss)	331				331
Ending Balance at Jun. 30, 2019	$ 51,142	$ 2	$ 115,532	$ 203	$ (64,595)
Ending Balance, Shares at Jun. 30, 2019	18,393,000	18,393,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities:
Net loss	$ (1,577,000)	$ (2,959,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity-based compensation	1,320,000	1,118,000
Depreciation	1,046,000	1,078,000
Noncash lease expense	201,000
Loss on disposal of fixed asset	11,000	55,000
Amortization of premium of marketable securities	44,000	160,000
Provision for bad debt		230,000
Deferred taxes		(535,000)
Equity loss in investee	428,000	491,000
Other	38,000	38,000
Changes in operating assets and liabilities:
Accounts receivable	368,000	(990,000)
Other current and long-term assets	183,000	22,000
Accounts payable	(124,000)	(1,344,000)
Accrued liabilities	(20,000)	1,288,000
Operating lease liabilities	(188,000)
Net cash provided by (used in) operations	1,730,000	(1,348,000)
Cash flow from investing activities:
Purchases of fixed assets	(633,000)	(1,152,000)
Purchase of marketable securities	(10,178,000)	(11,470,000)
Maturities of marketable securities	11,500,000	11,656,000
Purchase of equipment contributed to Equity Method Investee		(510,000)
Net cash (used in) provided by investing activities	689,000	(1,476,000)
Cash flow from financing activities:
Proceeds from exercise of stock options	9,000	9,000
Net cash provided by financing activities	9,000	9,000
Effect of exchange rate changes on cash and cash equivalents	1,000	(21,000)
Net decrease in cash	2,429,000	(2,836,000)
Cash balance at beginning of period	6,736,000	6,490,000
Cash balance at end of period	9,165,000	3,654,000
Supplemental disclosures of cash flow information:
Income taxes paid	20,000	1,000
Supplemental disclosures of non-cash investing and financing activities:
Fixed assets included in accounts payable	$ 5,000	$ 1,011,000

Overview and Basis of Presentat

Overview and Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Overview and Basis of Presentation	Note 1. Overview and Basis of Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These financial statements include the assets, liabilities, revenues and expenses of all wholly-owned subsidiaries and entities in which the Company has a controlling financial interest or is deemed to be the primary beneficiary. In determining whether the Company is the primary beneficiary of an entity, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. The Company uses the equity method to account for its investments in entities that it does not control, but in which it has the ability to exercise significant influence over operating and financial policies. All significant intercompany accounts and transactions are eliminated from the accompanying condensed consolidated financial statements. Nature of the Business Fulgent Genetics, Inc., together with its subsidiaries (collectively referred to as the “Company,” unless otherwise noted or the context otherwise requires), is a growing technology company offering comprehensive genetic testing and providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The Company has developed a proprietary technology platform that allows us to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing, or NGS, with our technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet specific customer needs. The Company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique genetic testing needs. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company’s financial statements and, in the opinion of management, all adjustments, which normal recurring , necessary for a fair of the financial position and results of results for periods are not necessarily indicative of the results be expected for The accompanying condensed consolidated balance sheet as of December 31, 2018 has been derived from the Company’s audited consolidated financial statements at that date but does not include all of the disclosures required by U.S. GAAP. with the Company’s audited consolidated financial statements included in the 2018 Annual Report, including the notes thereto.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies See the summary Company’s significant accounting policies set forth in the notes to its consolidated included in the 2018 Annual Report. Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. Actual results could differ from these estimates. On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) equity method investments. Foreign Currency Translation and Foreign Currency Transactions The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying condensed consolidated statements of stockholders’ equity. Gains and losses from these translations were not significant in the first six months of 2019 and 2018. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements were not significant Leases The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use (“ROU”) assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s condensed consolidated balance sheets. ROU lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since our leases do not provide an implicit rate. The ROU lease asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Concentration of Customers In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. In the three months ended June 30, 2019 , after aggregating customers that are under common control or are affiliates, two customers contributed 32% and 15%, respectively, of our revenue for the period. In the six months ended June 30, 2019, after aggregating customers that are under common control or are affiliates, two customers contributed 27% and 10%, respectively, of our revenue for the period. three and six months ended June 30, 2018 aggregating customers that are under common control or are affiliates, one customer contributed 13% of our revenue. Revenue from Contracts with Customers Disaggregation of Revenue The Company classifies its customers into three payor types, Clinical Institutional, Patients who pay directly or Clinical Insurance, as we believe this best depicts how the nature, amount, timing, and uncertainty of our revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the in the first six months of 2019 and 2018 Three months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 8,160 $ 4,782 Patient 143 156 Insurance 121 462 Total Revenue $ 8,424 $ 5,400 Six months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 13,279 $ 9,247 Patient 245 272 Insurance 270 534 Total Revenue $ 13,794 $ 10,053 Contract Balances Receivables from contracts with customers - As of June 30, 2019 and December 31, 2018, receivables from contracts with customers were approximately $5.5 million and $5.9 million, respectively, and are included within Trade accounts receivable on the Condensed Consolidated Balance Sheets. Contracts assets and liabilities - As of June 30, 2019 and December 31, 2018, contract assets and liabilities from contracts with customers were not material. Transaction Price Allocated to Future Performance Obligations The Company does not have material future obligations associated with Genetic Testing Services that extend beyond one year. Recent Accounting Pronouncements Adopted ASU No. 2016-02 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC 840, Leases See Note 9, Leases, for further information. ASU No. 2017-08 In March 2017, the FASB issued ASU No. 2017-08, Receivables–Nonrefundable Fees and Other Costs (Subtopic 310-20) ASU No. 2018-02 In February 2018, the FASB issued ASU 2018-02 Income Statement - Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which gives entities the option to reclassify to retained earnings the tax effects resulting from the Tax Act related to items in Additional Other Comprehensive Income (AOCI) that the FASB refers to as having been “stranded” in AOCI. The guidance is effective for annual and interim periods beginning after December 15, 2018, and is applicable to the Company in fiscal year 2019; however, early adoption is permitted. The Company adopted ASU 2018-02 as of January 1, 2019 and elected not to reclassify the income tax effect of the Tax Act from AOCI to retained earnings. The adoption of ASU 2018-02 resulted in no impact to the Company's financial statements. Recent Accounting Pronouncements The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Condensed Consolidated Financial Statements. ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief ASU No. 2018-15 In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

Marketable Securities

Marketable Securities	6 Months Ended
	Jun. 30, 2019
Investments Debt And Equity Securities [Abstract]
Marketable Securities	Note 3. Marketable Securities The Company’s marketable securities consisted of the following: June 30, 2019 Amortized Cost Basis Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Marketable securities: Short-term Money market accounts $ 3,722 — — $ 3,722 United States Treasury 999 — — 999 U.S. government agency securities 797 1 — 798 Corporate debt securities 16,014 22 (13 ) 16,023 Less: Cash equivalents (3,722 ) — — (3,722 ) Total short-term marketable securities 17,810 23 (13 ) 17,820 Corporate debt securities 11,561 136 — 11,697 Total long-term marketable securities 11,561 136 — 11,697 Total marketable securities $ 29,371 $ 159 $ (13 ) $ 29,517 December 31, 2018 Amortized Cost Basis Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Marketable securities: Short-term Money market accounts $ 2,692 $ — $ — $ 2,692 United States Treasury 990 — — 990 U.S. government agency securities 790 — — 790 Corporate debt securities 22,613 1 (96 ) 22,518 Less: Cash equivalents (2,692 ) — — (2,692 ) Total short-term marketable securities 24,393 1 (96 ) 24,298 Corporate debt securities 6,383 11 (8 ) 6,386 Total long-term marketable securities 6,383 11 (8 ) 6,386 Total marketable securities $ 30,776 $ 12 $ (104 ) $ 30,684 Management determined that the gross unrealized losses of $13,000 on the Company’s marketable securities as of June 30, 2019 were temporary in nature. Gross unrealized losses on the Company’s marketable securities were $104,000 as of December 31, 2018. The Company currently does not intend to sell these securities prior to maturity and does not consider these investments to be other-than-temporarily impaired as of June 30, 2019.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 4. Fair Value Measurements The authoritative guidance on fair value measurements establishes a framework with respect to measuring assets and liabilities at fair value on a recurring basis and non-recurring basis. Under the framework, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as of the measurement date. The framework also establishes a three-tier hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability and are developed based on the best information available in the circumstances. The hierarchy consists of the following three levels: Level 1: Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity can access at the measurement date. Level 2: Inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Inputs are unobservable inputs for the asset or liability. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: June 30, 2019 Total Level 1 Level 2 Level 3 (in thousands) Marketable securities and cash equivalents: Corporate debt securities $ 27,720 $ — $ 27,720 $ — United States Treasury 999 — 999 — U.S. government agency securities 798 — 798 — Money market accounts 3,722 3,722 — — Total marketable securities and cash equivalents $ 33,239 $ 3,722 $ 29,517 $ — December 31, 2018 Total Level 1 Level 2 Level 3 (in thousands) Marketable securities and cash equivalents: Corporate debt securities $ 28,904 $ — $ 28,904 $ — United States Treasury 990 — 990 — U.S. government agency securities 790 — 790 — Money market accounts 2,692 2,692 — — Total marketable securities and cash equivalents $ 33,376 $ 2,692 $ 30,684 $ — The Company’s Level 1 assets include money market instruments and are valued based upon observable market prices. Level 2 assets consist of United States Treasury, U.S. government agency securities, and corporate debt securities. Level 2 securities are valued based upon observable inputs that include reported trades, broker/dealer quotes, bids and offers. As of June 30, 2019, the Company had no investments that were measured using unobservable (Level 3) inputs. There were no transfers between fair value measurement levels during the first six months of 2019. Gross unrealized gains or losses for cash equivalents and marketable securities as of June 30, 2019 June 30, 2019 June 30

Fixed Assets

Fixed Assets	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Fixed Assets	Note 5. Fixed Assets Major classes of fixed assets consisted of the following: June 30, December 31, Useful Lives 2019 2018 (in thousands) Computer hardware 3 Years $ 1,687 $ 1,579 Computer software 3 Years 530 495 Medical lab equipment 5 Years 8,136 8,136 Furniture and fixtures 5 Years 234 233 Leasehold improvements Shorter of lease term or estimated useful life 802 802 Assets not yet placed in service 1,485 1,087 Total 12,874 12,332 Less: Accumulated depreciation (6,937 ) (5,886 ) Property and equipment, net $ 5,937 $ 6,446 Depreciation expense on fixed assets totaled $511,000 and $562,000 for the three months and $1.0 million and $1.1 million for the six months ended June 30, 2019 and 2018, respectively.

Significant Balance Sheet Accou

Significant Balance Sheet Accounts	6 Months Ended
	Jun. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Significant Balance Sheet Accounts	Note 6. Significant Balance Sheet Accounts Other current assets consisted of the following: June 30, 2019 December 31, 2018 (in thousands) Reagents $ 405 $ 314 Prepaid expenses 1,024 706 Prepaid income taxes 609 1,251 Marketable securities interest receivable 196 220 Other receivable 33 70 Total $ 2,267 $ 2,561 Reagents are used for DNA sequencing applications in the Company’s DNA sequencing equipment.

Reporting Segment and Geographi

Reporting Segment and Geographic Information	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	Note 7. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. All long-lived assets were located in the United States during the first half of 2019 and 2018. Revenue by region was as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Revenue: United States $ 6,686 $ 3,299 $ 10,300 $ 5,826 Foreign: Canada 516 1,070 1,054 2,040 Other Countries 1,222 1,031 2,440 2,187 Total $ 8,424 $ 5,400 $ 13,794 $ 10,053

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8. Commitments and Contingencies Operating Leases See Note 9, Leases, for further information. FF Gene Biotech See Note 14 for a description of the Company’s commitments related to its joint venture, FF Gene Biotech (as defined in Note 14). Purchase Obligations As of June 30, 2019, the Company had non-cancelable purchase obligations of $5.8 million for reagents, of which, $2.1 million is payable within twelve months, and $3.7 million is payable within the next twenty-four months. Contingencies From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial position, results of operations or cash flows.

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	Note 9. Leases The Company has various non-cancelable operating leases with varying terms through August 2023 primarily for office space. The Company has options to renew some of these leases for three years after their expiration. The determination of whether an arrangement contains a lease is made at inception by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The Company’s headquarters is located in Temple City, California, which is comprised of various corporate offices and a laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), accredited by the College of American Pathologists (“CAP”) and licensed by the State of California Department of Public Health. Additional offices are located in El Monte, California and Atlanta, Georgia and are used for certain research and development, customer service, report generation and other administrative functions. Rent expense was approximately $133,000 and $119,000 for the three months ended and $266,000 and $228,000 for the six months ended June 30, 2019 and 2018, respectively. The Company adopted new accounting standard ASC 842, Leases Our incremental borrowing rate was used to determine the present value of lease payments since our leases do not provide an implicit rate. The Company determined its incremental borrowing rate based on inquiries with our bank. The Company’s lease agreements do not contain any residual value guarantees, material restrictive covenants, bargain purchase options or asset retirement obligations. Lease expense for our operating leases is recognized on a straight-line basis over the lease term. Our leases do not contain variable lease payments. The Company does not have any short-term leases and thus has excluded short-term costs from the table below. The Company did not enter into any new leases during the six months ended June 30 The following was operating lease expense: Three months ended June 30, 2019 Six months ended June 30, 2019 Operating lease cost $ 146 $ 292 Supplemental cash flow information related to leases was the following: Three months ended June 30, 2019 Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 116 $ 278 Operating cash flows from operating leases $ 101 $ 201 Supplemental balance sheet information related to leases was the following: June 30, 2019 Weighted average remaining lease term - operating leases 6.1 years Weighted average discount rate - operating leases 6.25 % The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included: Operating Leases (in thousands) Year Ending December 31, 2019 (remaining 6 months) $ 281 2020 559 2021 550 2022 558 2023 567 2024 330 Thereafter 532 Total lease payments 3,377 Less imputed interest (591 ) Total $ 2,786 Future minimum payments under non-cancelable operating leases as of December 31, 2018 are as follows: Amounts (in thousands) Year ending December 31, 2019 $ 560 2020 559 2021 550 2022 558 2023 567 Thereafter 862 Total minimum lease payments $ 3,656

Equity-Based Compensation

Equity-Based Compensation	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity-Based Compensation	Note 10. Equity-Based Compensation The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Cost of revenue $ 167 $ 151 $ 309 $ 275 Research and development 233 171 411 303 Selling and marketing 186 113 311 221 General and administrative 151 138 289 319 Total $ 737 $ 573 $ 1,320 $ 1,118

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 11. Income Taxes Provision for income taxes consists of U.S. federal and state income taxes. A deferred tax liability is recognized for all taxable temporary differences, and a deferred tax asset is recognized for all deductible temporary differences, operating losses and tax credit carryforwards. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate for the full fiscal year ending December 31, 2019, which is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates, adjusted for discrete items recognized during the period. Certain significant or unusual items are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter. The Company’s effective tax rate was 1% and -2% for the three and six months ended June 30, 2019, respectively, compared with 11% and 18% for the three and six months ended June 30, 2018, respectively. The change in effective tax rate for the three months and six months ended June 30, 2019, was primarily attributable to the full valuation allowance.

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Loss per Share	Note 12. Loss per Share The following table presents the calculation of basic and diluted loss per share Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands, except per share data) Net income (loss) $ 331 $ (1,049 ) $ (1,577 ) $ (2,959 ) Weighted-average common shares—outstanding, basic 18,343 17,919 18,286 17,891 Weighted-average common shares—outstanding, diluted 19,021 17,919 18,286 17,891 Net income (loss) per common share, basic $ 0.02 $ (0.06 ) $ (0.09 ) $ (0.17 ) Net income (loss) per common share, diluted $ 0.02 $ (0.06 ) $ (0.09 ) $ (0.17 ) The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) Options 19 436 387 433 RSUs 358 1,055 1,093 961 The anti-dilutive shares described above were calculated using the treasury stock method. During the three months ended June 30, 2018 and the first six months ended June 30, 2019 and 2018, the Company had outstanding stock options and RSUs that were excluded from the weighted-average share calculation due to the Company’s net loss position.

Related Party

Related Party	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party	Note 13. Related Party Dr. Yun Yen, who is a member of the Company’s Board of Directors and a stockholder, serves as the President and Chairman of the Board for the Sino-American Cancer Foundation (the “Foundation”) and served as the President for the Taipei Medical University (the “University”), from August 1, 2011 through July 31, 2016. From time to time, the Company performs research testing services, on an arms-length basis, for the Foundation. The Company recognized $2,000 in revenue during the three and six months ended June 30, 2019 and zero for the three and six months ended June 30, 2018, as consideration for such services. Additionally, the Company subleased certain of its headquarters facilities to the Foundation. The Company recognized $8,000 and zero for the three months and $16,000 and $8,000 for the six months ended June 30, 2019 and 2018, respectively, as consideration for such sublease. As of June 30, 2019, and December 31, 2018, $2,000 and zero, respectively, was owed to the Company by the Foundation in connection with these relationships. From time to time, the Company performs genetic sequencing services, on an arms-length basis, for the University. The Company recognized $9,000 and $7,000 for the three months ended and $22,000 and $16,000 for the six months ended June 30, 2019 and 2018, respectively, as consideration for such services. As of June 30, 2019, and December 31, 2018, $18,000 and $51,000, respectively, was owed to the Company by the University in connection with this relationship. As more fully described in Note 14, in April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into a cooperation agreement (the “JV Agreement”) with Xilong Scientific Co., Ltd. (“Xilong Scientific”) and Fuzhou Jinqiang Investment Partnership (LP) (“FJIP”) to form a joint venture under the laws of the People’s Republic of China (“PRC”) called Fujian Fujun Gene Biotech Co., Ltd. (“FF Gene Biotech”). Xilong Scientific is an affiliate of Xi Long USA, Inc., a large stockholder of the Company that, as of , 2019, owned 11% of the outstanding shares of the Company’s common stock, and FJIP is owned by key management of FF Gene Biotech, including Dr. Han Lin Gao, the Chief Scientific Officer and a large stockholder of the Company and the owner of approximately 25% of FJIP. Fulgent Pharma utilizes space in the facility at which our laboratory and corporate headquarters are located. Since the completion of the Pharma Split-Off, Fulgent Pharma reimburses us for the portion of the rent we pay that is attributable to the space it uses, which amounts are not significant. As of June 30, 2019, and December 31, 2018, $29,000 and $22,000, respectively, was due from Fulgent Pharma as a result of this arrangement, which is recorded in Other receivable in Other current assets in the accompanying condensed consolidated balance sheets.

Equity Method Investments

Equity Method Investments	6 Months Ended
	Jun. 30, 2019
Equity Method Investments And Joint Ventures [Abstract]
Equity Method Investments	Note 14. Equity Method Investments In April 2017, the Company, through an affiliated company formed for the purpose of the relationship, entered into the JV Agreement with Xilong Scientific and FJIP to form FF Gene Biotech, a joint venture formed under the laws of the PRC to offer genetic testing services to customers in the PRC. Pursuant to the terms of the JV Agreement, the Company has agreed to contribute to FF Gene Biotech genetic sequencing and other equipment with a total cost of 60,000,000 renminbi (“ RMB”) over a five-year period for a 30% ownership interest in FF Gene Biotech, previously three-year per original agreement. Xilong Scientific has agreed to contribute to FF Gene Biotech 102,000,000 RMB over a five-year period for a 51% ownership interest in the FF Gene Biotech, previously three-year per original agreement. FJIP has agreed to contribute to FF Gene Biotech 19,000,000 RMB over a ten-year period for a 19% ownership interest in FF Gene Biotech, previously five-year per original agreement. The Company’s maximum exposure to fund losses of FF Gene Biotech as a result of its minority ownership of this entity is equal to its contribution obligation under the JV Agreement as described above. As of , 2019, 40.3 million RMB (or approximately $5.9 million U.S. dollars) remains to be contributed to the investee under the terms of the JV agreement. To date, the Company has purchased and contributed equipment with an aggregate fair value of $3.0 million pursuant to its contribution commitment under the JV Agreement. The Company accounted for this contribution in accordance with ASC 845, Nonmonetary Transactions , and recorded an investment based on the fair value of the contributed equipment, which is the same as carryover basis. The Company concluded FF Gene Biotech is a variable interest entity not have significant and Judgment regarding the level of influence over FF Gene Biotech includes consideration of key factors such as the Company's ownership interest, representation on the board of directors or other management body and participation in policy-making decisions. The Company accounts for its 30% interest in FF Gene Biotech using the equity method of accounting. The Company recorded its proportionate share of the losses of FF Gene Biotech in the three months ended , 2019 in the accompanying condensed consolidated statements of operations, and recorded its contribution to date, net of its proportionate share in the accumulated losses of FF Gene Biotech, in the accompanying condensed consolidated balance sheet as of , 2019. The Company entered into a license agreement with FF Gene Biotech, pursuant to which it granted FF Gene Biotech a license to use certain of the Company’s clinical molecular diagnostic gene detection technology and related software and proprietary reference library of genetic information, along with any improvements on this technology that they may develop during the term of the license agreement. Under the license agreement, FF Gene Biotech will pay to the Company, on a quarterly basis, certain royalties based on the revenues of FF Gene Biotech. The license agreement expired on December 31, 2018. The Company earned $17,000 and $35,000 for royalties under the license agreement for the three and ended June 30, 2018, respectively. In November 2017, FF Gene Biotech invested and formed a majority-owned subsidiary that focuses on sales and marketing for FF Gene Biotech. Equity method investments as of June 30 June 30, 2019 December 31, 2018 Carrying Value Ownership Percentage Carrying Value Ownership Percentage (in thousands) FF Gene Biotech $ 1,084 30 % $ 1,512 30 % Total equity method investments $ 1,084 30 % $ 1,512 30 % Summary Financial Information Summary financial information for FF Gene Biotech is as follows: June 30, December 31, 2019 2018 Consolidated Balance Sheets Data: (in thousands) Current Assets $ 2,367 $ 1,916 Non-Current Assets 3,892 4,068 Current Liabilities 4,318 2,415 Non-Current Liabilities — — Minority Interest 207 — Shareholders' Equity 1,734 3,569 Six Months Ended June 30 2019 2018 Consolidated Statements of Operations Data: (in thousands) Net Sales $ 1,131 $ 349 Gross Profit 579 (1 ) Net Loss (1,423 ) (1,637 ) Share of loss from investments accounted for using the equity method (1) (428 ) (491 ) (1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. These estimates, judgments and assumptions are based on historical data and experience available at the date of the accompanying condensed consolidated financial statements, as well as various other factors management believes to be reasonable under the circumstances. Actual results could differ from these estimates. On an on-going basis, management evaluates its estimates, primarily those related to: (i) revenue recognition criteria, (ii) accounts receivable and allowances for doubtful accounts, (iii) the useful lives of fixed assets, (iv) estimates of tax liabilities and (v) equity method investments.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company translates the assets and liabilities of its non-U.S. dollar functional currency subsidiaries into U.S. dollars using exchange rates in effect at the end of each period. Expenses for these subsidiaries are translated using rates that approximate those in effect during the period. Gains and losses from these translations are recognized in foreign currency translation included in other comprehensive income (loss) in the accompanying condensed consolidated statements of stockholders’ equity. Gains and losses from these translations were not significant in the first six months of 2019 and 2018. The Company and its subsidiaries that use the U.S. dollar as their functional currency remeasure monetary assets and liabilities at exchange rates in effect at the end of each period, and inventories, property and nonmonetary assets and liabilities at historical rates. Losses from these remeasurements were not significant
Leases	Leases The Company determines if an arrangement is a lease at inception. Operating leases are included as operating lease right-of-use (“ROU”) assets, operating lease liabilities, short-term, and operating lease liabilities, long-term, on the Company’s condensed consolidated balance sheets. ROU lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating ROU lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term, including options to extend the lease when it is reasonably certain that the Company will exercise that option. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments since our leases do not provide an implicit rate. The ROU lease asset includes any base rent payments made and excludes lease incentives and variable operating expenses. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
Concentration of Customers	Concentration of Customers In certain periods, a small number of customers has accounted for a significant portion of the Company’s revenue. In the three months ended June 30, 2019 , after aggregating customers that are under common control or are affiliates, two customers contributed 32% and 15%, respectively, of our revenue for the period. In the six months ended June 30, 2019, after aggregating customers that are under common control or are affiliates, two customers contributed 27% and 10%, respectively, of our revenue for the period. three and six months ended June 30, 2018 aggregating customers that are under common control or are affiliates, one customer contributed 13% of our revenue.
Revenue from Contracts with Customers	Revenue from Contracts with Customers Disaggregation of Revenue The Company classifies its customers into three payor types, Clinical Institutional, Patients who pay directly or Clinical Insurance, as we believe this best depicts how the nature, amount, timing, and uncertainty of our revenue and cash flows are affected by economic factors. The following table summarizes revenue from contracts with customers by payor type for the in the first six months of 2019 and 2018 Three months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 8,160 $ 4,782 Patient 143 156 Insurance 121 462 Total Revenue $ 8,424 $ 5,400 Six months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 13,279 $ 9,247 Patient 245 272 Insurance 270 534 Total Revenue $ 13,794 $ 10,053 Contract Balances Receivables from contracts with customers - As of June 30, 2019 and December 31, 2018, receivables from contracts with customers were approximately $5.5 million and $5.9 million, respectively, and are included within Trade accounts receivable on the Condensed Consolidated Balance Sheets. Contracts assets and liabilities - As of June 30, 2019 and December 31, 2018, contract assets and liabilities from contracts with customers were not material. Transaction Price Allocated to Future Performance Obligations The Company does not have material future obligations associated with Genetic Testing Services that extend beyond one year.
Recent Accounting Pronouncements Adopted and Recent Accounting Pronouncements	Recent Accounting Pronouncements Adopted ASU No. 2016-02 In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which supersedes ASC 840, Leases See Note 9, Leases, for further information. ASU No. 2017-08 In March 2017, the FASB issued ASU No. 2017-08, Receivables–Nonrefundable Fees and Other Costs (Subtopic 310-20) ASU No. 2018-02 In February 2018, the FASB issued ASU 2018-02 Income Statement - Reporting Comprehensive Income (ASC 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (AOCI), which gives entities the option to reclassify to retained earnings the tax effects resulting from the Tax Act related to items in Additional Other Comprehensive Income (AOCI) that the FASB refers to as having been “stranded” in AOCI. The guidance is effective for annual and interim periods beginning after December 15, 2018, and is applicable to the Company in fiscal year 2019; however, early adoption is permitted. The Company adopted ASU 2018-02 as of January 1, 2019 and elected not to reclassify the income tax effect of the Tax Act from AOCI to retained earnings. The adoption of ASU 2018-02 resulted in no impact to the Company's financial statements. Recent Accounting Pronouncements The Company evaluates all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in the Company’s disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on its Condensed Consolidated Financial Statements. ASU No. 2016-13 In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief ASU No. 2018-15 In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Accounting Standards Update 2014-09
Summary of Revenue from Contracts with Customers by Payor Type	The following table summarizes revenue from contracts with customers by payor type for the in the first six months of 2019 and 2018 Three months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 8,160 $ 4,782 Patient 143 156 Insurance 121 462 Total Revenue $ 8,424 $ 5,400 Six months ended June 30, 2019 2018 (in thousands) Genetic Testing Services by payor Institutional $ 13,279 $ 9,247 Patient 245 272 Insurance 270 534 Total Revenue $ 13,794 $ 10,053

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2019
Investments Debt And Equity Securities [Abstract]
Summary of Marketable Securities	The Company’s marketable securities consisted of the following: June 30, 2019 Amortized Cost Basis Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Marketable securities: Short-term Money market accounts $ 3,722 — — $ 3,722 United States Treasury 999 — — 999 U.S. government agency securities 797 1 — 798 Corporate debt securities 16,014 22 (13 ) 16,023 Less: Cash equivalents (3,722 ) — — (3,722 ) Total short-term marketable securities 17,810 23 (13 ) 17,820 Corporate debt securities 11,561 136 — 11,697 Total long-term marketable securities 11,561 136 — 11,697 Total marketable securities $ 29,371 $ 159 $ (13 ) $ 29,517 December 31, 2018 Amortized Cost Basis Unrealized Gains Unrealized Losses Aggregate Fair Value (in thousands) Marketable securities: Short-term Money market accounts $ 2,692 $ — $ — $ 2,692 United States Treasury 990 — — 990 U.S. government agency securities 790 — — 790 Corporate debt securities 22,613 1 (96 ) 22,518 Less: Cash equivalents (2,692 ) — — (2,692 ) Total short-term marketable securities 24,393 1 (96 ) 24,298 Corporate debt securities 6,383 11 (8 ) 6,386 Total long-term marketable securities 6,383 11 (8 ) 6,386 Total marketable securities $ 30,776 $ 12 $ (104 ) $ 30,684

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis, based on the three-tier fair value hierarchy: June 30, 2019 Total Level 1 Level 2 Level 3 (in thousands) Marketable securities and cash equivalents: Corporate debt securities $ 27,720 $ — $ 27,720 $ — United States Treasury 999 — 999 — U.S. government agency securities 798 — 798 — Money market accounts 3,722 3,722 — — Total marketable securities and cash equivalents $ 33,239 $ 3,722 $ 29,517 $ — December 31, 2018 Total Level 1 Level 2 Level 3 (in thousands) Marketable securities and cash equivalents: Corporate debt securities $ 28,904 $ — $ 28,904 $ — United States Treasury 990 — 990 — U.S. government agency securities 790 — 790 — Money market accounts 2,692 2,692 — — Total marketable securities and cash equivalents $ 33,376 $ 2,692 $ 30,684 $ —

Fixed Assets (Tables)

Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2019
Property Plant And Equipment [Abstract]
Major Classes of Fixed Assets	Major classes of fixed assets consisted of the following: June 30, December 31, Useful Lives 2019 2018 (in thousands) Computer hardware 3 Years $ 1,687 $ 1,579 Computer software 3 Years 530 495 Medical lab equipment 5 Years 8,136 8,136 Furniture and fixtures 5 Years 234 233 Leasehold improvements Shorter of lease term or estimated useful life 802 802 Assets not yet placed in service 1,485 1,087 Total 12,874 12,332 Less: Accumulated depreciation (6,937 ) (5,886 ) Property and equipment, net $ 5,937 $ 6,446

Significant Balance Sheet Acc_2

Significant Balance Sheet Accounts (Tables)	6 Months Ended
	Jun. 30, 2019
Balance Sheet Related Disclosures [Abstract]
Schedule of Other Current Assets	Other current assets consisted of the following: June 30, 2019 December 31, 2018 (in thousands) Reagents $ 405 $ 314 Prepaid expenses 1,024 706 Prepaid income taxes 609 1,251 Marketable securities interest receivable 196 220 Other receivable 33 70 Total $ 2,267 $ 2,561

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenue by region was as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Revenue: United States $ 6,686 $ 3,299 $ 10,300 $ 5,826 Foreign: Canada 516 1,070 1,054 2,040 Other Countries 1,222 1,031 2,440 2,187 Total $ 8,424 $ 5,400 $ 13,794 $ 10,053

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Schedule of Operating Lease Expense	The following was operating lease expense: Three months ended June 30, 2019 Six months ended June 30, 2019 Operating lease cost $ 146 $ 292
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was the following: Three months ended June 30, 2019 Six months ended June 30, 2019 Cash paid for amounts included in the measurement of lease liabilities $ 116 $ 278 Operating cash flows from operating leases $ 101 $ 201
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was the following: June 30, 2019 Weighted average remaining lease term - operating leases 6.1 years Weighted average discount rate - operating leases 6.25 %
Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis	The following is a maturity analysis of operating lease liabilities using undiscounted cash flows on an annual basis with renewal periods included: Operating Leases (in thousands) Year Ending December 31, 2019 (remaining 6 months) $ 281 2020 559 2021 550 2022 558 2023 567 2024 330 Thereafter 532 Total lease payments 3,377 Less imputed interest (591 ) Total $ 2,786
Schedule of Future Minimum Payments for Noncancelable Operating Leases	Future minimum payments under non-cancelable operating leases as of December 31, 2018 are as follows: Amounts (in thousands) Year ending December 31, 2019 $ 560 2020 559 2021 550 2022 558 2023 567 Thereafter 862 Total minimum lease payments $ 3,656

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Equity-Based Compensation	The Company has included equity-based compensation expense as part of cost of revenue and operating expenses in the accompanying condensed consolidated statements of operations as follows: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) (in thousands) Cost of revenue $ 167 $ 151 $ 309 $ 275 Research and development 233 171 411 303 Selling and marketing 186 113 311 221 General and administrative 151 138 289 319 Total $ 737 $ 573 $ 1,320 $ 1,118

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Reconciliation of the Basic and Diluted Loss Per Share Computations	The following table presents the calculation of basic and diluted loss per share Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands, except per share data) Net income (loss) $ 331 $ (1,049 ) $ (1,577 ) $ (2,959 ) Weighted-average common shares—outstanding, basic 18,343 17,919 18,286 17,891 Weighted-average common shares—outstanding, diluted 19,021 17,919 18,286 17,891 Net income (loss) per common share, basic $ 0.02 $ (0.06 ) $ (0.09 ) $ (0.17 ) Net income (loss) per common share, diluted $ 0.02 $ (0.06 ) $ (0.09 ) $ (0.17 )
Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share	The following securities have been excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2019 2018 2019 2018 (in thousands) Options 19 436 387 433 RSUs 358 1,055 1,093 961

Equity Method Investments (Tabl

Equity Method Investments (Tables)	6 Months Ended
	Jun. 30, 2019
Equity Method Investments And Joint Ventures [Abstract]
Schedule of Equity Method Investments	Equity method investments as of June 30 June 30, 2019 December 31, 2018 Carrying Value Ownership Percentage Carrying Value Ownership Percentage (in thousands) FF Gene Biotech $ 1,084 30 % $ 1,512 30 % Total equity method investments $ 1,084 30 % $ 1,512 30 %
Summary of Financial Information for Equity Method Investees	Summary Financial Information Summary financial information for FF Gene Biotech is as follows: June 30, December 31, 2019 2018 Consolidated Balance Sheets Data: (in thousands) Current Assets $ 2,367 $ 1,916 Non-Current Assets 3,892 4,068 Current Liabilities 4,318 2,415 Non-Current Liabilities — — Minority Interest 207 — Shareholders' Equity 1,734 3,569 Six Months Ended June 30 2019 2018 Consolidated Statements of Operations Data: (in thousands) Net Sales $ 1,131 $ 349 Gross Profit 579 (1 ) Net Loss (1,423 ) (1,637 ) Share of loss from investments accounted for using the equity method (1) (428 ) (491 ) (1) The Company's share of loss is based on pro-rated net loss beginning April 25, 2017, the date on which the Company entered into the JV Agreement.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019USD ($)Customer	Jun. 30, 2018Customer	Jun. 30, 2019USD ($)Customer	Jun. 30, 2018Customer	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)
Summary Of Significant Accounting Policies [Line Items]
Trade accounts receivable, net of allowance for doubtful accounts of $585 and $590, as of June 30, 2019 and December 31, 2018, respectively	$ 5,543		$ 5,543			$ 5,948
Practical expedient not to disclose amount of transaction price allocated to unsatisfied performance obligations			true
Operating lease liabilities	2,786		$ 2,786		$ 3,000
Right-of-use assets	$ 2,756		$ 2,756		$ 3,000
Customer Concentration Risk | Revenue
Summary Of Significant Accounting Policies [Line Items]
Number of customers | Customer	2	1	2	1
Customer Concentration Risk | Revenue | Customer One
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	32.00%	13.00%	27.00%	13.00%
Customer Concentration Risk | Revenue | Customer Two
Summary Of Significant Accounting Policies [Line Items]
Concentration risk, percentage	15.00%		10.00%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Revenue from Contracts with Customers by Payor Type (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Accounting Standards Update 2014-09
Disaggregation Of Revenue [Line Items]
Type of Revenue [Extensible List]	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember	flgt:GeneticTestingServicesMember
Revenue from contracts with customers by payor type	$ 8,424	$ 5,400	$ 13,794	$ 10,053
Accounting Standards Update 2014-09 | Clinical Institutional Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	8,160	4,782	13,279	9,247
Accounting Standards Update 2014-09 | Clinical Patient Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	143	156	245	272
Accounting Standards Update 2014-09 | Clinical Insurance Contracts
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers by payor type	$ 121	$ 462	$ 270	$ 534

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	$ 29,371	$ 30,776
Marketable securities, Unrealized Gains	159	12
Marketable securities, Unrealized Losses	(13)	(104)
Marketable securities, Aggregate Fair Value	29,517	30,684
Cash and cash equivalents	9,165	6,736	$ 3,654	$ 6,490
Less: cash equivalents	(3,722)	(2,692)
Short-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	17,810	24,393
Marketable securities, Unrealized Gains	23	1
Marketable securities, Unrealized Losses	(13)	(96)
Marketable securities, Aggregate Fair Value	17,820	24,298
Short-Term Marketable Securities | Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	16,014	22,613
Marketable securities, Unrealized Gains	22	1
Marketable securities, Unrealized Losses	(13)	(96)
Marketable securities, Aggregate Fair Value	16,023	22,518
Short-Term Marketable Securities | United States Treasury
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	999	990
Marketable securities, Aggregate Fair Value	999	990
Short-Term Marketable Securities | U.S. Government Agency Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	797	790
Marketable securities, Unrealized Gains	1
Marketable securities, Aggregate Fair Value	798	790
Long-Term Marketable Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	11,561	6,383
Marketable securities, Unrealized Gains	136	11
Marketable securities, Unrealized Losses		(8)
Marketable securities, Aggregate Fair Value	11,697	6,386
Long-Term Marketable Securities | Corporate Debt Securities
Schedule of Available For Sale Securities [Line Items]
Marketable securities, Amortized Cost Basis	11,561	6,383
Marketable securities, Unrealized Gains	136	11
Marketable securities, Unrealized Losses		(8)
Marketable securities, Aggregate Fair Value	11,697	6,386
Short Term Marketable Securities | Money Market Accounts
Schedule of Available For Sale Securities [Line Items]
Cash and cash equivalents	3,722	2,692
Cash and cash equivalents fair value disclosure	$ 3,722	$ 2,692

Marketable Securities - Additio

Marketable Securities - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Investments Debt And Equity Securities [Abstract]
Gross unrealized loss	$ 13,000	$ 104,000

Fair Value Measurements - Infor

Fair Value Measurements - Information about Financial Assets Measured at Fair Value on Recurring Basis Based on Three-Tier Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 29,517	$ 30,684
Fair Value Measurements Recurring
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	33,239	33,376
Fair Value Measurements Recurring | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	3,722	2,692
Fair Value Measurements Recurring | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	29,517	30,684
Fair Value Measurements Recurring | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities and cash equivalents	0	0
Fair Value Measurements Recurring | Money Market Accounts
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,722	2,692
Fair Value Measurements Recurring | Money Market Accounts | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	3,722	2,692
Fair Value Measurements Recurring | Money Market Accounts | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring | Money Market Accounts | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents fair value disclosure	0	0
Fair Value Measurements Recurring | United States Treasury
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	999	990
Fair Value Measurements Recurring | United States Treasury | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring | United States Treasury | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	999	990
Fair Value Measurements Recurring | United States Treasury | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring | Corporate Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	27,720	28,904
Fair Value Measurements Recurring | Corporate Debt Securities | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring | Corporate Debt Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	27,720	28,904
Fair Value Measurements Recurring | Corporate Debt Securities | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring | U.S. Government Agency Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	798	790
Fair Value Measurements Recurring | U.S. Government Agency Securities | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	0	0
Fair Value Measurements Recurring | U.S. Government Agency Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	798	790
Fair Value Measurements Recurring | U.S. Government Agency Securities | Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 0	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details)	3 Months Ended
	Jun. 30, 2019USD ($)
Fair Value Disclosures [Abstract]
Fair value asset, investments measured using unobservable inputs	$ 0
Fair value assets, transfers between levels, amount	0
Unrealized losses for securities in an unrealized loss position for more than 12 months	13,000
Other-than-temporary impairment losses related to marketable securities	$ 0

Fixed Assets - Major Classes of

Fixed Assets - Major Classes of Fixed Assets (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 12,874	$ 12,332
Less: Accumulated depreciation	(6,937)	(5,886)
Fixed assets, net	5,937	6,446
Computer Hardware
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,687	1,579
Useful life in years	3 years
Computer Software
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 530	495
Useful life in years	3 years
Medical Lab Equipment
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 8,136	8,136
Useful life in years	5 years
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 234	233
Useful life in years	5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 802	802
Useful life in years	Shorter of lease term or estimated useful life
Assets Not Yet Placed in Service
Property Plant And Equipment [Line Items]
Fixed assets, gross	$ 1,485	$ 1,087

Fixed Assets - Additional Infor

Fixed Assets - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Property Plant And Equipment [Abstract]
Depreciation expense on fixed assets	$ 511,000	$ 562,000	$ 1,046,000	$ 1,078,000

Significant Balance Sheet Acc_3

Significant Balance Sheet Accounts - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Reagents	$ 405	$ 314
Prepaid expenses	1,024	706
Prepaid income taxes	609	1,251
Marketable securities interest receivable	196	220
Other receivable	33	70
Total	$ 2,267	$ 2,561

Reporting Segment and Geograp_3

Reporting Segment and Geographical Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2019Segment
Segment Reporting [Abstract]
Number of reporting segments	1

Reporting Segment and Geograp_4

Reporting Segment and Geographical Information - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenue	$ 8,424	$ 5,400	$ 13,794	$ 10,053
United States
Segment Reporting Information [Line Items]
Revenue	6,686	3,299	10,300	5,826
Canada
Segment Reporting Information [Line Items]
Revenue	516	1,070	1,054	2,040
Other Countries
Segment Reporting Information [Line Items]
Revenue	$ 1,222	$ 1,031	$ 2,440	$ 2,187

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - Reagents $ in Millions	Jun. 30, 2019USD ($)
Commitments And Contingencies [Line Items]
Non-cancelable purchase obligations	$ 5.8
Non-cancelable purchase obligations, payable within next twenty-four months	3.7
Non-cancelable purchase obligations, payable within twelve months	$ 2.1

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 01, 2019
Leases [Abstract]
Operating leases term of expiration			2023-08
Operating leases, renewal term	3 years		3 years
Operating leases, rent expense	$ 133,000	$ 119,000	$ 266,000	$ 228,000
Long-term ROU assets	2,756,000		2,756,000		$ 3,000,000
Short-term lease liabilities	401,000		401,000		384,000
Long-term lease liabilities	$ 2,385,000		2,385,000		$ 2,600,000
Impact to retained earnings upon adoption ASC 842			$ 0

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 146	$ 292

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 116	$ 278
Operating cash flows from operating leases	$ 101	$ 201

Leases - Schedule of Suppleme_2

Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)	Jun. 30, 2019
Leases [Abstract]
Weighted average remaining lease term - operating leases	6 years 1 month 6 days
Weighted average discount rate - operating leases	6.25%

Leases - Schedule of Maturity A

Leases - Schedule of Maturity Analysis of Operating Lease Liabilities using Undiscounted Cash Flows on an Annual Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Leases [Abstract]
2019 (remaining 6 months)	$ 281
2020	559
2021	550
2022	558
2023	567
2024	330
Thereafter	532
Total lease payments	3,377
Less imputed interest	(591)
Total	$ 2,786	$ 3,000

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments for Noncancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 560
2020	559
2021	550
2022	558
2023	567
Thereafter	862
Total minimum lease payments	$ 3,656

Equity-Based Compensation - Sum

Equity-Based Compensation - Summary of Equity-Based Compensation Expenses as Part of Cost of Revenue and Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 737	$ 573	$ 1,320	$ 1,118
Cost of Revenue
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	167	151	309	275
Research and Development
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	233	171	411	303
Selling and Marketing
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	186	113	311	221
General and Administrative
Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Equity-based compensation expense	$ 151	$ 138	$ 289	$ 319

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Effective income tax rate	1.00%	11.00%	(2.00%)	18.00%

Loss per Share - Reconciliation

Loss per Share - Reconciliation of Basic and Diluted Loss Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net income (loss)	$ 331	$ (1,049)	$ (1,577)	$ (2,959)
Weighted-average common shares—outstanding, basic	18,343	17,919	18,286	17,891
Weighted-average common shares—outstanding, diluted	19,021	17,919	18,286	17,891
Net income (loss) per common share, basic	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)
Net income (loss) per common share, diluted	$ 0.02	$ (0.06)	$ (0.09)	$ (0.17)

Loss per Share - Anti-dilutive

Loss per Share - Anti-dilutive Securities Excluded from Calculation of Diluted Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	19	436	387	433
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted loss per share	358	1,055	1,093	961

Related Party - Additional Info

Related Party - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Apr. 30, 2017
Related Party Transaction [Line Items]
Ownership percentage	30.00%		30.00%		30.00%
Xilong Scientific
Related Party Transaction [Line Items]
Ownership percentage of common stock outstanding shares	11.00%		11.00%
Foundation
Related Party Transaction [Line Items]
Revenue from related parties	$ 8,000	$ 0	$ 16,000	$ 8,000
Due from related parties	2,000		2,000		$ 0
Foundation | Research Testing Services
Related Party Transaction [Line Items]
Revenue from related parties	2,000	0	2,000	0
University
Related Party Transaction [Line Items]
Revenue from related parties	9,000	$ 7,000	22,000	$ 16,000
Due from related parties	$ 18,000		$ 18,000		51,000
FF Gene Biotech | FJIP
Related Party Transaction [Line Items]
Ownership percentage						19.00%
FF Gene Biotech | Dr. Han Lin Gao | FJIP
Related Party Transaction [Line Items]
Ownership percentage	25.00%		25.00%
Fulgent Pharma
Related Party Transaction [Line Items]
Due from related parties	$ 29,000		$ 29,000		$ 22,000

Equity Method Investments - Add

Equity Method Investments - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2017CNY (¥)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Jun. 30, 2019CNY (¥)	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Ownership interest to be made in joint venture		30.00%		30.00%		30.00%	30.00%
Royalty earned | $		$ 8,424,000	$ 5,400,000	$ 13,794,000	$ 10,053,000
Royalty | License Agreement
Schedule Of Equity Method Investments [Line Items]
Royalty earned | $			$ 17,000		$ 35,000
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture | ¥	¥ 60,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	30.00%	30.00%		30.00%		30.00%	30.00%
Contributions remain for joint venture		$ 5,900,000		$ 5,900,000		¥ 40,300,000
FF Gene Biotech | Equipment
Schedule Of Equity Method Investments [Line Items]
Contributions made to joint venture | $				$ 3,000,000
Xilong Scientific | FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture | ¥	¥ 102,000,000
Contribution period in joint venture	5 years
Previous contribution period in joint venture	3 years
Ownership interest to be made in joint venture	51.00%
FJIP | FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Contribution to be made in joint venture | ¥	¥ 19,000,000
Contribution period in joint venture	10 years
Previous contribution period in joint venture	5 years
Ownership interest to be made in joint venture	19.00%

Equity Method Investments - Sch

Equity Method Investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Apr. 30, 2017
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,084	$ 1,512
Ownership percentage	30.00%	30.00%
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Carrying Value	$ 1,084	$ 1,512
Ownership percentage	30.00%	30.00%	30.00%

Equity Method Investments - Sum

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Balance Sheet Data (Details) - FF Gene Biotech - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Schedule Of Equity Method Investments [Line Items]
Current Assets	$ 2,367	$ 1,916
Non-Current Assets	3,892	4,068
Current Liabilities	4,318	2,415
Minority Interest	207
Shareholders' Equity	$ 1,734	$ 3,569

Equity Method Investments - S_2

Equity Method Investments - Summary of Financial Information for Equity Method Investees, Statement of Operations Data (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Schedule Of Equity Method Investments [Line Items]
Equity loss in investee	$ (149)	$ (246)	$ (428)	$ (491)
FF Gene Biotech
Schedule Of Equity Method Investments [Line Items]
Net Sales			1,131	349
Gross Profit			579	(1)
Net Loss			(1,423)	(1,637)
Equity loss in investee			$ (428)	$ (491)